Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application

被引:10
作者
Zhou, Ting [1 ,2 ]
Ding, Li [1 ]
Li, Xiaomin [2 ]
Zhang, Fei [2 ]
Zhang, Qian [3 ]
Gong, Bing [1 ]
Guo, Xiaofeng [1 ]
机构
[1] China Pharmaceut Univ, Dept Pharmaceut Anal, Nanjing 210009, Peoples R China
[2] Jiangsu Simcere Pharmaceut R & D Co Ltd, Nanjing 210042, Peoples R China
[3] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
关键词
iguratimod; pharmacokinetics; HPLC;
D O I
10.1002/bmc.921
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-performance liquid chromatographic method with UV detection has been developed for the determination of iguratimod (T-614) in rat plasma. Plasma was precipitated with acetonitrile after the addition of the internal standard (IS), N-[4-(2-formylaminoacetyl)-5-methoxy-2-phenoxyphenyl]-methanesulfonamide. The chromatographic separation was achieved on a reversed-phase C-18 column with the mobile phase acetonitrile-acetic acid aqueous solution, pH 4.5 (40:60, v/v), at a flow rate of 1 mL/min, and the UV detection wavelength was set at 257 nm. The calibration curve was linear over the range 0.10-50.0 mu g/mL, and the lower limit of quantification was 0.10 mu g/rnL. The intra- and inter-day relative standard deviations were all less than 11.5%. The method has been successfully applied to study the pharmacokinetics of iguratimod in rats. A single 10 mg/kg dose of iguratimod was given to the rats by intragastric administration. The mean maximum plasma concentration of iguratimod for the six rats was 14.5 mu g/mL, and the mean elimination half-life of iguratimod was 4.0 h. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:260 / 264
页数:5
相关论文
共 7 条
  • [1] An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with 1κBα degradation
    Aikawa, Y
    Yamamoto, M
    Yamamoto, T
    Morimoto, K
    Tanaka, K
    [J]. INFLAMMATION RESEARCH, 2002, 51 (04) : 188 - 194
  • [2] [Anonymous], 2001, Guidance for industry, bioanalytical method validation
  • [3] Hara Masako, 2007, Mod Rheumatol, V17, P1, DOI 10.1007/s10165-006-0542-y
  • [4] Kohno M, 2001, J RHEUMATOL, V28, P2591
  • [5] LI HY, 2005, PHARM J, V40, P222
  • [6] Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice
    Tanaka, K
    Yamamoto, T
    Aikawa, Y
    Kizawa, K
    Muramoto, K
    Matsuno, H
    Muraguchi, A
    [J]. RHEUMATOLOGY, 2003, 42 (11) : 1365 - 1371
  • [7] TANAKA K, 1992, ARZNEIMITTEL-FORSCH, V42-2, P935